Messenger RNA Market Research Report 2025-2035, Competitive Analysis of Pfizer, GSK, Arcturus Therapeutics, AstraZeneca, Beam Therapeutics, Moderna, Oncotelic, SK Bioscience, Sangamo, Sano...
Arcturus Therapeutics Holdings Inc. (ARCT)
Last arcturus therapeutics holdings inc. earnings: 3/11 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arcturusrx.com/investor-relations
Company Research
Source: Yahoo! Finance
Driven by public-private investments, the industry sees pharmaceutical giants like Pfizer and Moderna spearheading innovations. Despite challenges such as high costs, the market is set for substantial growth through 2035, with North America leading due to its robust healthcare infrastructure. Recent collaborations, such as Etherna Immunotherapies with Dropshot Therapeutics, are further accelerating RNA therapeutic developments. Dublin, June 11, 2025 (GLOBE NEWSWIRE) -- The "Messenger RNA Market - A Global and Regional Analysis: Focus on Application and Regional Analysis - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The global messenger RNA market is currently in the growth stage of its lifecycle, driven by the rapid success of mRNA vaccines, particularly for COVID-19, which has expanded its applications to other infectious diseases and therapeutic areas such as cancer and genetic disorders. This growth is supported by significant i
Show less
Read more
Impact Snapshot
Event Time:
ARCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARCT alerts
High impacting Arcturus Therapeutics Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ARCT
News
- Arcturus Therapeutics to Attend Upcoming Investor ConferenceBusiness Wire
- Arcturus Therapeutics (NASDAQ:ARCT) had its price target lowered by analysts at Citigroup Inc. from $12.00 to $9.00. They now have a "neutral" rating on the stock.MarketBeat
- Arcturus Therapeutics (NASDAQ:ARCT) had its price target lowered by analysts at Piper Sandler from $140.00 to $72.00. They now have an "overweight" rating on the stock.MarketBeat
- Arcturus Therapeutics (NASDAQ:ARCT) had its price target lowered by analysts at HC Wainwright from $12.00 to $9.00. They now have a "neutral" rating on the stock.MarketBeat
- Arcturus Therapeutics Holdings Inc (ARCT) Q3 2025 Earnings Call Highlights: Navigating ... [Yahoo! Finance]Yahoo! Finance
ARCT
Earnings
- 11/10/25 - Beat
ARCT
Sec Filings
- 12/19/25 - Form 4
- 12/19/25 - Form 4
- 12/19/25 - Form 4
- ARCT's page on the SEC website